Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

Service

Funding, debt advisory & ECM

Parties

Talk to the deal team

Geoff Nash

Director

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

Medicija has acquired Saulės Šeimos Medicinos Centras

Healthcare

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Learn more

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Healthcare

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Learn more

SRT Marine has completed a placing and subscription

TMT

SRT Marine has completed a placing and subscription

SRT Marine Systems plc has announced an equity raise of at least US$22 million at US$1.10 per share representing a 5.75% discount, through a US$19.4 million accelerated bookbuild placing and a US$2 million subscription by Ocean Infinity, alongside a separate retail offer of up to US$1.3 million.

Learn more